Core Viewpoint - TaiLing Pharmaceutical (01011) resumed trading today, experiencing a significant drop of over 16% at one point, and currently down 8.97% at HKD 0.71, with a trading volume of HKD 2.8566 million [1] Group 1 - The company was temporarily suspended from trading yesterday afternoon and resumed trading this morning [1] - On August 19, the company announced that it received a request from the Hong Kong government to assist in verifying a contract related to an independent third party [1] - The matter does not impact the company's daily operations, and as of the announcement date, the company's directors and senior management have no legal liabilities [1]

Core Viewpoint - 泰凌医药's stock experienced significant volatility upon resuming trading, initially dropping over 16% before stabilizing to a decline of 8.97% at HKD 0.71, with a trading volume of HKD 2.8566 million [1] Group 1 - 泰凌医药 was temporarily suspended from trading prior to its resumption this morning [1] - The company received a request from Hong Kong government authorities to assist in verifying a contract related to an independent third party [1] - The matter raised by the authorities does not impact the company's daily operations [1] Group 2 - As of the announcement date, the company's directors and senior management have no legal liabilities related to the matter [1]

Core Viewpoint - 泰凌医药's shares will resume trading on August 20, 2025, at 9:00 AM [1] Company Summary - 泰凌医药 has announced the resumption of its share trading, indicating a potential return to normal operations and investor interest [1]

智通财经APP讯，泰凌医药(01011)发布公告，该公司的股份将于2025年8月20日上午9时正起恢复买卖。 ...

格隆汇8月20日丨泰凌医药(01011.HK)发布公告，该公司的股份将于今天(20/8/2025)上午九时正起恢复 买卖。 ...

Core Viewpoint - 泰凌医药 has received a request from the Hong Kong government to assist in verifying a contract related to an independent third party, which does not impact its daily operations [1] Company Operations - The company stated that the matter does not affect its daily business activities [1] - As of the announcement date, the company's directors and senior management have no legal liabilities [1] Stock Trading - The company's stock was suspended from trading at 1 PM on August 19, 2025, at its request [1] - Trading is planned to resume at 9 AM on August 20, 2025 [1]

公司已向联交所申请于2025年8月20日星期三上午九时正起恢复股份买卖。 智通财经APP讯，泰凌医药(01011)发布公告，于2025年8月19日，公司接到香港有关政府部门要求，协 助查实与公司独立第三方有关的一份合约。此事项对公司日常业务没有影响。截至本公告日，公司董事 和高阶管理层亦没有法律责任。 ...

泰凌医药(01011)发布公告，于2025年8月19日，公司接到香港有关政府部门要求，协助查实与公司独立 第三方有关的一份合约。此事项对公司日常业务没有影响。截至本公告日，公司董事和高阶管理层亦没 有法律责任。 公司已向联交所申请于2025年8月20日星期三上午九时正起恢复股份买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 內幕消息及恢復買賣 應 本 公 司 之 要 求，本 公 司 之 股 份 已 於 二 零 二 五 年 八 月 十 九 日 星 期 二 下 午 一 時 正 起 暫 停 買 賣，以 待 刊 發 本 公 告。本 公 司 已 向 聯 交 所 申 請 於 二 零 二 五 年 八 月 二 十 日 星 期 三 上 午 九 時 正 起 恢 復 股 份 買 賣。 承董事會命 中國泰凌醫藥集團有限公司 董事會主席 吳 鐵 香 港，二 零 二 五 年 八 月 十 九 日 於 本 公 告 日 期，執 行 董 事 為 吳 鐵 先 生 及 吳 靜 美 女 士；非 執 行 董 事 為 錢 唯 博 士 及 錢 余 女 士；及 獨 立 非 執 行 董 事 為 余 梓 山 先 生、趙 玉 彪 博 士 及 吳 銘 軍 先 生。 本 ...

Core Viewpoint - 泰凌医药 announced a suspension of trading for its shares on the Hong Kong Stock Exchange due to the pending release of an announcement containing insider information [1] Group 1 - The trading suspension will take effect on August 19, 2025, at 1:00 PM [1] - The suspension is requested by the company itself [1] - The announcement is expected to contain significant insider information relevant to the company [1]